228 related articles for article (PubMed ID: 32725245)
1. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer.
Sheth RA; Murthy R; Hong DS; Patel S; Overman MJ; Diab A; Hwu P; Tam A
JAMA Netw Open; 2020 Jul; 3(7):e207911. PubMed ID: 32725245
[TBL] [Abstract][Full Text] [Related]
2. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
[TBL] [Abstract][Full Text] [Related]
4. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
5. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.
Drescher C; Drexler K; Hilber H; Schmidt B; Haferkamp S
J Dtsch Dermatol Ges; 2019 Mar; 17(3):321-323. PubMed ID: 30698924
[No Abstract] [Full Text] [Related]
6. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery.
Goldberg EP; Hadba AR; Almond BA; Marotta JS
J Pharm Pharmacol; 2002 Feb; 54(2):159-80. PubMed ID: 11848280
[TBL] [Abstract][Full Text] [Related]
7. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
Suh RD; Goldin JG; Wallace AB; Sheehan RE; Heinze SB; Gitlitz BJ; Figlin RA
Radiology; 2004 May; 231(2):359-64. PubMed ID: 15128982
[TBL] [Abstract][Full Text] [Related]
8. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
9. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
[TBL] [Abstract][Full Text] [Related]
10. Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC.
Shahrouki P; Lee JM; Barclay J; Khan SN; Genshaft S; Abtin F; Dubinett SM; Lisberg A; Sharma S; Garon EB; Suh R
JTO Clin Res Rep; 2021 Nov; 2(11):100242. PubMed ID: 34806054
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Approaches for the Treatment of Melanoma.
Bommareddy PK; Silk AW; Kaufman HL
Cancer J; 2017; 23(1):40-47. PubMed ID: 28114253
[TBL] [Abstract][Full Text] [Related]
12. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
13. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
[TBL] [Abstract][Full Text] [Related]
14. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunotherapy: using the tumor as the remedy.
Marabelle A; Tselikas L; de Baere T; Houot R
Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
[TBL] [Abstract][Full Text] [Related]
16. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
Gupta M; Brennan DC; Alhamad T
Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
[No Abstract] [Full Text] [Related]
17. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
18. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
19. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy.
De Lombaerde E; De Wever O; De Geest BG
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188526. PubMed ID: 33617921
[TBL] [Abstract][Full Text] [Related]
20. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
